tgoop.com/Clinical_Elite_Batch_4/47
Last Update:
💊الجديد في الأدوية💊
صرحت هيئة الغذاء والدواء الأميركية دواء جديد بشكل حقن لمعالجة خمول الغدة الجاردرقية
تاريخ الاعتماد ٩/٨/٢٠٢٤
💠 اسم الدواء palopegteriparatide
الاسم التجاري الاوريجنال "Yorvipath"
In 9/8/2024, the U.S. Food and Drug Administration has approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism.
بالرغم من اعتماد الهيئة لهذا الدواء لمعالجة خمول الجاردرقية إلا أنه لم تجرى اي دراسة لاستخدام هذا الدواء في حالة خمول الجاردرقية الحاد بعد الجراحة لذلك لا يستخدم في هذه الحالة
🔻Yorvipath was not studied in adults with acute post-surgical hypoparathyroidism.
Ⓜ️Prodrug of parathyroid hormone
💠Mechanism of Action
Releases PTH(1-34) to maintain a continuous systemic exposure
Endogenous PTH maintains extracellular calcium and phosphate homeostasis by increasing serum calcium and decreasing serum phosphate
These effects are mediated by stimulating bone turnover to mobilize calcium and phosphate from bone, promoting renal calcium reabsorption and phosphate excretion, and facilitating active vitamin D synthesis, in turn increasing intestinal absorption of calcium and phosphate
Similar to endogenous PTH, PTH(1-34) released from palopegteriparatide exerts these effects through its main receptor, parathyroid hormone 1 receptor (PTH1R), which is highly expressed on osteoblasts, osteocytes, renal tubular cells, and in several other tissues
@Ibnalsofi
BY القناة الإعلامية لدفعة النخبة السريرية_Clinical Elite
Share with your friend now:
tgoop.com/Clinical_Elite_Batch_4/47